Crispr Gene-Editing Drugs Show Promise in Preliminary Study

Posted on AllSides September 16th, 2022
From The Center

Intellia Therapeutics Inc. reported encouraging early-stage study results for its Crispr gene-editing treatments, the latest sign that the pathbreaking technology could result in commercially available drugs in the coming years.

Intellia said Friday that one of its treatments, code-named NTLA-2002, significantly reduced levels of a protein that causes periodic attacks of swelling in six patients with a rare genetic disease called hereditary angioedema, or HAE.

Read full story
Some content from this outlet may be limited or behind a paywall.

Wall Street Journal (News)

AllSides Media Bias Rating: Center
AllSides Media Bias Rating: Center
109831/85706
See full bias rating for Wall Street Journal (News)
Learn about media bias
https://www.wsj.com/articles/crispr-gene-editing-drugs-show-promise-in-preliminary-study-11663327063

More News about Science from the Left, Center and Right

From the Left

From the Center

From the Right